应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IMMU Immunomedics
停牌 07-14 16:18:14 EDT
87.86
+0.00
0.00%
最高
87.86
最低
87.86
成交量
0.00
今开
87.86
昨收
87.86
日振幅
0.00%
总市值
203.24亿
流通市值
179.93亿
总股本
2.31亿
成交额
0.00
换手率
0.00%
流通股本
2.05亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
FDA批准Keytruda® (帕博利珠单抗)及Keytruda Qlex™ (帕博利珠单抗与贝拉透明质酸酶阿尔法-pmph)分别与Trodelvy® (戈沙妥珠单抗-hziy)联用,作为PD-L1+ (CPS≥10)晚期三阴性乳腺癌的一线治疗
美股速递 · 06-25
FDA批准Keytruda® (帕博利珠单抗)及Keytruda Qlex™ (帕博利珠单抗与贝拉透明质酸酶阿尔法-pmph)分别与Trodelvy® (戈沙妥珠单抗-hziy)联用,作为PD-L1+ (CPS≥10)晚期三阴性乳腺癌的一线治疗
加载更多
公司概况
公司名称:
Immunomedics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Immunomedics, Inc.于1982年在特拉华州组成,是一家生物制药公司,主要专注于为癌症、自身免疫缺陷以及其他严重疾病的专门治疗研发单细胞克隆和基于抗体的产品。公司已经发展了大量先进的专利技术,这些技术能创造适用于人类的抗体,这些抗体可以不作标记单一使用(即裸露的),或是可以与放射性同位素、化疗药物、细胞因子或毒素结合而使用,在每一种情况下创造高目标性受体。利用这些技术,公司制造了大量不同活动机制的治疗剂产品替代物。公司也是第一家将抗体组合作为可能的高效癌症治疗方法而进行测试的公司之一,因此也开始了开发双重功能单细胞克隆抗体,该抗体针对同一癌细胞上的2个不同的抗原发生作用。
发行价格:
--
{"stockData":{"symbol":"IMMU","market":"US","secType":"STK","nameCN":"Immunomedics","latestPrice":87.86,"timestamp":1603396800000,"preClose":87.86,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":204793526,"shares":231320559,"eps":-1.703018,"marketStatus":"停牌","change":0,"latestTime":"07-14 16:18:14 EDT","open":87.86,"high":87.86,"low":87.86,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.703018,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784073600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":436942800000,"exchange":"NASDAQ","adjPreClose":87.86,"volumeRatio":0},"requestUrl":"/m/hq/s/IMMU","defaultTab":"news","newsList":[{"id":"1126203598","title":"FDA批准Keytruda® (帕博利珠单抗)及Keytruda Qlex™ (帕博利珠单抗与贝拉透明质酸酶阿尔法-pmph)分别与Trodelvy® (戈沙妥珠单抗-hziy)联用,作为PD-L1+ (CPS≥10)晚期三阴性乳腺癌的一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1126203598","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126203598?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:48","pubTimestamp":1782384501,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已批准将Keytruda 以及Keytruda Qlex 分别与Trodelvy 联合使用,作为程序性死亡配体1阳性且综合阳性分数不低于10的晚期三阴性乳腺癌患者的一线治疗方案。这一重要监管决定为这类难治性乳腺癌患者提供了新的初始治疗选择。Keytruda及其组合产品Keytruda Qlex,均来自默沙东,将与Immunomedics的Trodelvy协同作战,靶向攻击PD-L1高表达的晚期三阴性乳腺癌。晚期三阴性乳腺癌因其雌激素受体、孕激素受体及HER2均呈阴性而得名,治疗选择历来有限,预后较差。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","LU1989771016.USD","SG9999002232.USD","IE00BLSP4452.SGD","SG9999001176.USD","LU1934455863.HKD","LU0208291251.USD","LU1037948897.HKD","LU0266013472.USD","IE0009355771.USD","LU0985320562.USD","LU1699723380.USD","LU1917777945.USD","LU2106854487.HKD","LU2125154778.USD","LU1934455194.USD","LU1941712264.USD","IE000M9KFDE8.USD","LU0211331839.USD","LU0265550359.USD","LU2125154935.USD","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU1066051225.USD","LU0861579265.USD","LU2461242641.AUD","LU0238689110.USD","LU2023250843.SGD","SG9999014559.SGD","LU1585245621.USD","LU1989772923.USD","LU1934455277.USD","SG9999014567.USD","LU0965508806.USD","LU1989772840.SGD","LU0234572021.USD","LU2023250504.SGD","LU0130517989.USD","LU2491050071.SGD","IE00BLSP4239.USD","LU1923622614.USD","SGXZ57979304.SGD","LU0006306889.USD","LU1061106388.HKD","LU2433249047.HKD","LU1974910355.USD","LU2357627491.SGD","LU2360032135.SGD","LU2491049909.HKD","LU0070302665.USD","LU1066053197.SGD","LU1116320901.HKD","LU2112291526.USD","LU1983299246.USD","LU2361045086.USD","LU0106261372.USD","LU0265550946.USD","IE00B2B36J28.USD","LU0320765489.SGD","LU0965509283.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU2125909593.SGD","LU0098860793.USD","LU0432979614.USD","LU1023059063.AUD","SG9999015358.SGD","LU2491050154.USD","MRK","SG9999015341.SGD","LU0477156953.USD","LU0203345920.USD","LU0289739699.SGD","LU1116320737.USD","SG9999001440.SGD","BK4533","BK4534","IE00BBT3K403.USD","LU0868494617.USD","LU1066051498.USD","LU0130102774.USD","LU0320765646.SGD","LU0965509101.SGD","LU1571399168.USD","LU0058720904.USD","LU1066051811.HKD","LU0648001328.SGD","BK4516","LU2089984988.USD","LU1201861249.SGD","BK4588","LU0122379950.USD","LU1430594728.SGD","BK4007","LU2361044865.SGD","LU1069347547.HKD","IE00BFTCPJ56.SGD","SG9999014575.USD","LU1929549753.HKD","LU1035773651.USD","SG9999013999.USD","LU0965509010.AUD","IMMU","LU1093756325.SGD","IE00BSNM7G36.USD","LU0980610538.SGD","LU1162221912.USD","LU2468319806.SGD","SG9999001176.SGD","BK4550","LU2324357040.USD","LU2361044949.HKD","LU2125909247.SGD","SG9999014542.SGD","LU0203347892.USD","LU1291159041.SGD","IE00BN8TJ469.HKD","LU1037948541.HKD","IE00BJJMRZ35.SGD","SG9999002224.SGD","IE0002141913.USD","BK4559","LU1941712348.USD","LU0868494708.USD","BK4585","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunomedics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0788},{"period":"6month","weight":0.0852},{"period":"1year","weight":0.2013},{"period":"ytd","weight":0.0986}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immunomedics, Inc.于1982年在特拉华州组成,是一家生物制药公司,主要专注于为癌症、自身免疫缺陷以及其他严重疾病的专门治疗研发单细胞克隆和基于抗体的产品。公司已经发展了大量先进的专利技术,这些技术能创造适用于人类的抗体,这些抗体可以不作标记单一使用(即裸露的),或是可以与放射性同位素、化疗药物、细胞因子或毒素结合而使用,在每一种情况下创造高目标性受体。利用这些技术,公司制造了大量不同活动机制的治疗剂产品替代物。公司也是第一家将抗体组合作为可能的高效癌症治疗方法而进行测试的公司之一,因此也开始了开发双重功能单细胞克隆抗体,该抗体针对同一癌细胞上的2个不同的抗原发生作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.638889,"avgChangeRate":0.040069},{"month":2,"riseRate":0.416667,"avgChangeRate":0.00479},{"month":3,"riseRate":0.5,"avgChangeRate":0.031025},{"month":4,"riseRate":0.444444,"avgChangeRate":0.030925},{"month":5,"riseRate":0.567568,"avgChangeRate":0.098275},{"month":6,"riseRate":0.378378,"avgChangeRate":-0.028307},{"month":7,"riseRate":0.459459,"avgChangeRate":-0.022873},{"month":8,"riseRate":0.567568,"avgChangeRate":0.066879},{"month":9,"riseRate":0.513514,"avgChangeRate":-0.00046},{"month":10,"riseRate":0.513514,"avgChangeRate":0.014771},{"month":11,"riseRate":0.527778,"avgChangeRate":0.055185},{"month":12,"riseRate":0.583333,"avgChangeRate":0.172556}],"exchange":"NASDAQ","name":"Immunomedics","nameEN":"Immunomedics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunomedics(IMMU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immunomedics(IMMU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immunomedics,IMMU,Immunomedics股票,Immunomedics股票老虎,Immunomedics股票老虎国际,Immunomedics行情,Immunomedics股票行情,Immunomedics股价,Immunomedics股市,Immunomedics股票价格,Immunomedics股票交易,Immunomedics股票购买,Immunomedics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunomedics(IMMU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immunomedics(IMMU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}